A recent study has revealed a potential connection between glucosamine use and the acceleration of Alzheimer's disease progression in individuals with mild cognitive impairment (MCI). Researchers discovered that those who took glucosamine were significantly more likely to advance to dementia compared to non-users. This investigation, published on June 9 in Nature Metabolism, utilized a comprehensive analysis of patient health records alongside advanced imaging techniques applied to human brain tissue and mouse models of Alzheimer's.
While the findings do not establish a direct causative link between glucosamine and dementia, they contribute to the growing body of evidence indicating that metabolic dysfunction plays a crucial role in neurodegenerative conditions. Dr. Ramon Sun, the lead author and director of the Center for Advanced Spatial Biomolecule Research at UF's McKnight Brain Institute, noted the importance of this research, especially considering that approximately 7 million individuals in the U.S. are living with Alzheimer's and many are taking this widely available supplement.
Impact of Glucosamine on Dementia Risk
Given glucosamine's popularity among older adults for joint health, the research aimed to explore its potential influence on Alzheimer's and related dementias (ADRD). Collaborating with fellow researchers Dr. Yi Guo and Dr. Jiang Bian, the team employed artificial intelligence to analyze deidentified health records from UF Health, focusing on patients diagnosed with ADRD or MCI.
The analysis revealed that glucosamine was commonly used among these patients, with 1,896 individuals diagnosed with ADRD and 2,750 with MCI reporting its use, accounting for approximately 8% of each group. After adjusting for various demographic factors, the study found that glucosamine users had a 25% increased likelihood of progressing from MCI to dementia. Furthermore, a similar 25% increase in mortality risk was noted among those already diagnosed with ADRD, suggesting that the supplement's effects may vary depending on disease stage.
Exploring Metabolic Pathways
The study identified a specific biological process that could elucidate this association. Researchers found that a protein and sugar-tagging pathway is overly active in Alzheimer's disease, presenting a potential target for future interventions. Dr. Sun emphasized the significance of addressing metabolic abnormalities in conjunction with traditional Alzheimer's treatments focused on plaques and tangles.
Glucosamine, a naturally occurring sugar-related molecule, can cross the blood-brain barrier and participate in biochemical pathways that influence protein sugar structures. This research indicates that glucosamine's effects may be heavily influenced by the biological context in which it operates.
Insights from Animal Models and Human Tissue
Further investigation using genetically modified mice supported the hypothesis that glucosamine enhances sugar molecule attachment to proteins, leading to worsened social memory deficits. Conversely, reducing this sugar-tagging activity improved memory performance. Additionally, analysis of human brain tissue from the UF Neuromedicine Brain and Tissue Bank revealed significantly elevated sugar attachment levels in Alzheimer's specimens compared to healthy controls.
These findings suggest that metabolic abnormalities may actively contribute to Alzheimer's disease progression rather than merely arising as a consequence. Dr. Matt Gentry, a co-author of the study, highlighted the necessity for further clinical inquiry into this association.